$GILD Company News Gilead says EU Committee to
Post# of 89391
Posted On: 08/03/2014 10:33:33 AM
$GILD Company News
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
Gilead trounces estimates for earnings, sales, Sovaldi 4:17 p.m. July 23, 2014 - Russ Britt
Gilead Sovaldi sales reach $3.48B, ahead of $2.87B view 4:10 p.m. July 23, 2014 - Russ Britt
Gilead's $6.53B in revs. beats $5.85B estimate 4:10 p.m. July 23, 2014 - Russ Britt
Gilead adj. earns are $2.36/share vs. view of $1.79 4:09 p.m. July 23, 2014 - Russ Britt
Gilead revs. $6.5 billion vs. year-ago $2.77 billion 4:08 p.m. July 23, 2014 - Russ Britt
Gilead Q2 net is $2.20 vs. year-ago 46 cents 4:07 p.m. July 23, 2014 - Russ Britt
4 ways Gilead’s earnings will impact every American 1:30 p.m. July 23, 2014 - Tim Mullaney
Gilead's moment of truth arrives: How does Sovaldi impact earnings? 1:18 p.m. July 23, 2014 - blogs.marketwatch.com
CVS officials say Sovaldi pricing in line with history, but unsustainable 3:36 p.m. July 20, 2014 - blogs.marketwatch.com
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
A Quick Look At 2 Small-Cap Bio-Pharmaceutical Companies: Discovery Labs And Exelexis 9:22 p.m. Aug. 1, 2014 - Seeking Alpha
TAL Education, Team Health Join The IBD 50 Resistance 6:08 p.m. Aug. 1, 2014 - Investors Business Daily
Pharmacyclics Q2 Earnings Get Mixed Reception 11:35 a.m. Aug. 1, 2014 - Investors Business Daily
Micron: Maybe It Isn't Different This Time 1:30 p.m. July 31, 2014 - Seeking Alpha
Amgen Makes the Cut 12:25 p.m. July 31, 2014 - Barrons.com
A Tough Market For The 'Risk On' Investor 10:50 a.m. July 31, 2014 - Seeking Alpha
Stock Market News for July 31, 2014 - Market News 10:10 a.m. July 31, 2014 - Zacks.com
Biotech Earnings Put These ETFs in Focus - ETF News And Commentary 10:01 a.m. July 31, 2014 - Zacks.com
3 Biotech Catalyst Stocks To Own 9:04 a.m. July 31, 2014 - Seeking Alpha
Biotech Valuations Are Low Not Stretched. Here's Why. 8:35 a.m. July 31, 2014 - TheStreet.com
Cramer's Lightning Round - 6 Biotech Picks (7/30/14) 6:35 a.m. July 31, 2014 - Seeking Alpha
7 Stocks With High Sales Growth To Watch After Yesterday's GDP Data 6:06 a.m. July 31, 2014 - Seeking Alpha
Can the Earnings Rebound be Sustained? - Earnings Trends 3:34 a.m. July 31, 2014 - Zacks.com
Can the Earnings Rebound be Sustained? - Earnings Outlook 3:34 a.m. July 31, 2014 - Zacks.com
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong 7:55 p.m. July 30, 2014 - TheStreet.com
Merck, J&J, Baxter Provide Healthy Dividend Stream 6:01 p.m. July 30, 2014 - Investors Business Daily
WellPoint Lifts View Despite Profit Drop 12:04 p.m. July 30, 2014 - The Wall Street Journal Interactive Edition
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog 12:04 p.m. July 30, 2014 - Zacks.com
Why Humana (HUM) Stock Is Declining Today 11:58 a.m. July 30, 2014 - TheStreet.com
Stock Market News for July 30, 2014 - Market News 10:10 a.m. July 30, 2014 - Zacks.com
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. July 14, 2014 - PR Newswire - PRF
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus 6:30 a.m. July 1, 2014 - PR Newswire - PRF
AIDSVu Releases New Maps that Depict Impact of HIV in American Cities 9:50 a.m. June 27, 2014 - BusinessWire - BZX
Top White House AIDS Official Visits San Francisco Clinic on National HIV Testing Day 9:00 a.m. June 27, 2014 - PR Newswire - PRF
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C 3:01 a.m. June 27, 2014 - BusinessWire - BZX
Biotechnology Equities Technical Notes -- Research on StemCells, Gilead Sciences, Galena Biopharma, and Inovio Pharma 7:10 a.m. June 26, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17 5:00 p.m. June 16, 2014 - BusinessWire - BZX
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan 8:00 p.m. June 15, 2014 - BusinessWire - BZX
Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors 3:30 p.m. June 13, 2014 - PR Newswire - PRF
Critical Alerts For Ralph Lauren, Rackspace Hosting, Gilead Sciences, Fortinet, and Express Scripts Technology Released By InvestorsObserver 9:31 a.m. June 13, 2014 - PR Newswire - PRF
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
Gilead trounces estimates for earnings, sales, Sovaldi 4:17 p.m. July 23, 2014 - Russ Britt
Gilead Sovaldi sales reach $3.48B, ahead of $2.87B view 4:10 p.m. July 23, 2014 - Russ Britt
Gilead's $6.53B in revs. beats $5.85B estimate 4:10 p.m. July 23, 2014 - Russ Britt
Gilead adj. earns are $2.36/share vs. view of $1.79 4:09 p.m. July 23, 2014 - Russ Britt
Gilead revs. $6.5 billion vs. year-ago $2.77 billion 4:08 p.m. July 23, 2014 - Russ Britt
Gilead Q2 net is $2.20 vs. year-ago 46 cents 4:07 p.m. July 23, 2014 - Russ Britt
4 ways Gilead’s earnings will impact every American 1:30 p.m. July 23, 2014 - Tim Mullaney
Gilead's moment of truth arrives: How does Sovaldi impact earnings? 1:18 p.m. July 23, 2014 - blogs.marketwatch.com
CVS officials say Sovaldi pricing in line with history, but unsustainable 3:36 p.m. July 20, 2014 - blogs.marketwatch.com
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
A Quick Look At 2 Small-Cap Bio-Pharmaceutical Companies: Discovery Labs And Exelexis 9:22 p.m. Aug. 1, 2014 - Seeking Alpha
TAL Education, Team Health Join The IBD 50 Resistance 6:08 p.m. Aug. 1, 2014 - Investors Business Daily
Pharmacyclics Q2 Earnings Get Mixed Reception 11:35 a.m. Aug. 1, 2014 - Investors Business Daily
Micron: Maybe It Isn't Different This Time 1:30 p.m. July 31, 2014 - Seeking Alpha
Amgen Makes the Cut 12:25 p.m. July 31, 2014 - Barrons.com
A Tough Market For The 'Risk On' Investor 10:50 a.m. July 31, 2014 - Seeking Alpha
Stock Market News for July 31, 2014 - Market News 10:10 a.m. July 31, 2014 - Zacks.com
Biotech Earnings Put These ETFs in Focus - ETF News And Commentary 10:01 a.m. July 31, 2014 - Zacks.com
3 Biotech Catalyst Stocks To Own 9:04 a.m. July 31, 2014 - Seeking Alpha
Biotech Valuations Are Low Not Stretched. Here's Why. 8:35 a.m. July 31, 2014 - TheStreet.com
Cramer's Lightning Round - 6 Biotech Picks (7/30/14) 6:35 a.m. July 31, 2014 - Seeking Alpha
7 Stocks With High Sales Growth To Watch After Yesterday's GDP Data 6:06 a.m. July 31, 2014 - Seeking Alpha
Can the Earnings Rebound be Sustained? - Earnings Trends 3:34 a.m. July 31, 2014 - Zacks.com
Can the Earnings Rebound be Sustained? - Earnings Outlook 3:34 a.m. July 31, 2014 - Zacks.com
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong 7:55 p.m. July 30, 2014 - TheStreet.com
Merck, J&J, Baxter Provide Healthy Dividend Stream 6:01 p.m. July 30, 2014 - Investors Business Daily
WellPoint Lifts View Despite Profit Drop 12:04 p.m. July 30, 2014 - The Wall Street Journal Interactive Edition
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog 12:04 p.m. July 30, 2014 - Zacks.com
Why Humana (HUM) Stock Is Declining Today 11:58 a.m. July 30, 2014 - TheStreet.com
Stock Market News for July 30, 2014 - Market News 10:10 a.m. July 30, 2014 - Zacks.com
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. July 14, 2014 - PR Newswire - PRF
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus 6:30 a.m. July 1, 2014 - PR Newswire - PRF
AIDSVu Releases New Maps that Depict Impact of HIV in American Cities 9:50 a.m. June 27, 2014 - BusinessWire - BZX
Top White House AIDS Official Visits San Francisco Clinic on National HIV Testing Day 9:00 a.m. June 27, 2014 - PR Newswire - PRF
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C 3:01 a.m. June 27, 2014 - BusinessWire - BZX
Biotechnology Equities Technical Notes -- Research on StemCells, Gilead Sciences, Galena Biopharma, and Inovio Pharma 7:10 a.m. June 26, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17 5:00 p.m. June 16, 2014 - BusinessWire - BZX
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan 8:00 p.m. June 15, 2014 - BusinessWire - BZX
Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors 3:30 p.m. June 13, 2014 - PR Newswire - PRF
Critical Alerts For Ralph Lauren, Rackspace Hosting, Gilead Sciences, Fortinet, and Express Scripts Technology Released By InvestorsObserver 9:31 a.m. June 13, 2014 - PR Newswire - PRF
(0)
(0)